Brief: Can-Fite Submits Market Registration Plan To EMA For Psoriasis Drug
10/01/2023 12:14
Jan 10 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE SUBMITS MARKET REGISTRATION PLAN TO EUROPEAN
MEDICINES
AGENCY FOR PICLIDENOSON IN THE TREATMENT OF PSORIASIS; FDA
SUBMISSION TO FOLLOW
Source text for Eikon: ID:nBwbCYqJZa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage